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Abstract 
Mental disorders contribute to 13% of the global burden of disease. With major depressive 
disorder (MDD) expected to be the most significant contributor by 2030, the economic and 
social impact of this burden will be substantial.  There have been various factors linked to the 
underlying pathophysiology of MDD, including a deficit in individual vital neurotransmitter 
connections between specific neurons, and alterations in the expression of the transcription 
factors cyclic AMP response element-binding protein (CREB) and the brain-derived 
neurotrophic factor (BDNF) in the brain.  Ketamine, an N-methyl-D-aspartate receptor 
(NMDAR) rantagonist and an -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
receptor (AMPAR) stimulator has  officialy been used as an anesthetic and analgesic drug since 
the 1970s, until recently when it was approved for the management and treatment of MDD.  
Ketamine works by altering and rebalancing the monoaminergic, glutamatergic and GABArgic 
sytems to stimulate new synaptic connections, better memory, and improved brain plasticity. 
However, there are limited published studies that demonstrate the direct relationship between 
ketamine, brain neurotransmitters levels, gene and protein expression in the management of 
MDD. 
In this study, we investigated the pharmacodynamic effects of ketamine in the brain by 
assessing changes in monoaminergic, glutaminergic and GABAergic neurotransmitter levels 
using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Furthermore, we 
investigated the links between ketamine and the expression of transcription factors, cyclic AMP 
response element-binding protein (CREB) and brain-derived neurotrophic factor (BDNF) in 
treatment of depression using quantitative real-time polymerase chain reaction (qPCR) 
analysis. Twenty-one healthy male Sprague-Dawley (SD) rats were administered 15 mg/kg of 
ketamine via intraperitoneal administration at different time points (N = 3 per time point). 
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Experimental animals were euthanized by decapitation post-administration of ketamine, and 
brain samples were harvested for analysis. 
As per LC-MS/MS and qPCR, the pharmacodynamic results demonstrated that ketamine s 
anti-depressive mechanism of action is due to alteration of the glutamatergic system which 
occurs via the disinhibition of glutamate release, which further boosts central nervous 
synaptogenesis, hence maintaining the in-balance neurotransmitters and genes associated with 
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Thesis outline  
The presented Master s thesis is organized in discrete chapters, with each containing its 
references as follows: 
Chapter 1: Presents the general introduction and literature review of major depressive 
disorder, various factors contributing to its pathophysiology, and its prevalence in Sub-Saharan 
African countries. Chapter 1 further outlines the use of ketamine and other anti-depressant 
medication in the treatment of the major depressive disorder. Moreover, chapter one describes 
in-depth the analytical techniques, study aims and objectives of this current study. 
Chapter 2: Presents the full manuscript for this study, which was submitted for publication. 
The manuscript is titled; Investigations into the pharmacodynamic effects of Ketamine by 
evaluating its effect on brain neurotransmitter levels and CREB/BDNF expression.  
Submitted to: The Journal of Biological Psychiatry (Manuscript number: BPS-D-20-01782) 
Chapter 3: Presents a brief discussion of the thesis, conclusion, limitations, future 
recommendations, and appendix for this study.
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1.1.  Major depressive disorder (MDD) 
Major depressive disorder (MDD), also known as clinical depression, is a chronic mental 
disorder that persists for at least two weeks, severe enough to cause significant problems in a 
patients' ability to uphold personal relations, meet school or work obligations, and partake in 
previously normal communal activities (1, 2).  MDD is characterized by a high frequency of 
non-recovery and relapse, leading to suicidal ideation and morbidity (3-5).  It is a multifaceted 
and common condition that poses significant challenges to both the patients and physicians 
who treat it and is habitually misdiagnosed as melancholic depression (6, 7). According to the 
new World Health Organization (WHO) report, it is projected that over 300 million people are 
affected by MDD, with an estimated 16.6% lifetime prevalence (2, 8, 9). This number is 
projected to increase, with an estimated projection of 46 million people in the United States 
being diagnosed with MDD by 2050 (2).  
World Health Organization cites MDD as the leading cause of worldwide disability and is 
projected to become the second leading cause of worldwide disease and disability by 2030 (8, 
10-13).  Currently, the cause of MDD is suggested to be due to genetic, biological, 
environmental, and psychological factors (9).  However, MDD frequently develops during 
young adulthood (14).  Young adulthood is a developmental stage in life between the ages of 
18 and 25 years, where an accumulative exposure to risk factors, such as uncertainty in finding 
employment, exploring identity, and enhanced self-focus increases the possibility of 
developing mental health problems (14).  Since MDD is exclusively diagnosed by behavioral 
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1.2.  Brain neurotransmitters and major depressive disorder 
The cause of depressive illness has been linked to brain monoaminergic neuronal dysfunction 
(15, 16).  Specific symptoms are allied with the increase or depletion of specific 
neurotransmitters (NTs), which suggest that specific symptoms of depression can be assigned 
to specific neurotransmitter or cascade of neurotransmitter changes (15, 17).  The three central 
monoamine neurotransmitter systems associated with the pathophysiological changes in 
depression are serotonin (5-HT), norepinephrine (NE) and dopamine (DA) (15, 17-19).  This 
led  to the development of the monoamine theory of depression, which states that mental 
depression is due to deficit of brain monoaminergic activity and that depression is treated by 
drugs that increase this activity (11).  Figure 1 shows the chemical structures of 5-HT, NE, and 
DA. 
 
Figure 1: Monoamine neurotransmitters, a) Dopamine, b) Serotonin, and c) Norepinephrine. (Created by the 
author using ChemDraw Professional 17.1). 
 
The monoamine neurotransmitter systems have mainly been linked in the pathophysiology of 
MDD not only due to their role in the therapeutic response that results from pharmacological 
targeting of these systems but also since their location in the brain overlap with the mood-
Page | 4  
 
regulating pathways (20). Figure 2 shows the role of monoamine neurotransmitters in 
regulating mood, attention, interest, alertness, energy, anxiety and obsession, and shows how 
they can contribute to the development of mental disorders due to monoamine deficits.  
Impairment of these functions is all prominent characteristics of MDD; thus, any changes in 
the monoamine neurotransmitter system may enhance negative emotions or depressive moods, 
hence aggravating MDD by potentiating these symptoms (20, 21).  The changes or disturbance 
in the levels of the neurotransmitters may result from impairments in their synthesis, release, 
transportation and reuptake (21).   
 
Figure 2: Monoamine regulation of mood and behavior. Adapted from Open Access literature 
https://drjockers.com/dopamine/ and (17).  
In recent years, it has been proven that alteration of the monoamine neurotransmitters is not 
sufficient in explaining the pathophysiology underlying MDD (22). Hence, other brain 
neurotransmitters have also been studied and linked to the pathophysiology of MDD.  These 
brain neurotransmitters include gamma-Aminobutyric Acid (GABA) and glutamate (Glut) (23, 
24).  GABA is the principal neurotransmitter that mediates neural inhibition, and it is mainly 
responsible for balancing and fine-tuning of excitatory neurotransmission of several neuronal 
systems, including the glutamatergic and monoaminergic neurotransmitter systems (22, 23). 
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Various studies have indicated that there is a significant decrease in GABA levels in various 
brain regions of MDD patients and stressed rodents (22, 23, 25). Similar observations have 
been made with the major excitatory neurotransmitter in the central nervous system (glutamate) 
(26, 27). Glut plays a critical role in significant brain functions such as plasticity, brain 
development, neuronal survival, and it serves as a metabolic precursor for GABA (25, 28).  
Figure 3 shows the structure of glutamate and GABA. 
 
Figure 3: Chemical structure of a) Glutamate and b) GABA Neurotransmitters. (Created by the author using 
ChemDraw Professional 17.1). 
 
1.3.  Gene expression and major depressive disorder 
Brain-derived neurotrophic factor (BDNF) a gene which encodes for BDNF protein along with 
cyclic adenosine monophosphate response element-binding protein (CREB) has been 
commonly implicated in the pathophysiology of major depressive illness (29, 30). 
1.3.1.  Brain-derived neurotrophic factor (BDNF) gene 
BDNF is one of the many neurotrophic factors that regulate the formation and plasticity of 
neuronal networks in the brain and peripheral nervous system (31, 32). Hence, BDNF is crucial 
to the survival, growth and maintenance of neurons in critical brain circuitry involved in 
emotional and cognitive function (32).  Its binding mediates the action of BDNF on specific 
receptors, such as the tropomyosin receptor kinase (Trk) receptors, which are responsible for 
controlling synaptic plasticity and strength of the mammalians nervous system (31, 33).  Recent 
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in vivo studies have shown that stress reduces BDNF expression in the hippocampus and 
frontal cortex which leads to the development of depression in the later stages of life (31).  A 
similar observation was made in MDD patients, where BDNF levels were reduced in the 
hippocampus of post-mortem samples taken from patients who have committed suicide (32). 
Different classes of antidepressants have been found to increase BDNF expression in the brain; 
furthermore increasing the levels of BDNF in the brain have shown antidepressant-like effects 
(31).  These findings have made it plausible that decreased levels of BDNF induce a state of 
increased susceptibility to stress and depression (32).  Based on this a neurotrophic hypothesis 
of depression was proposed, which states that the loss of BDNF plays a vital function in the 
pathophysiology of depression and that its restoration may represent a critical mechanism 
underlying antidepressant efficacy (34).  Figure 4 shows the proposed neurotrophic hypothesis 
of depression. 
 
Figure 4: Schematic diagram outlining the proposed neurotrophic pathophysiology of depression. Reprinted from 
Open source literature (34). 
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1.3.2.  Cyclic adenosine monophosphate response element-binding protein  
Cyclic Adenosine monophosphate response element-binding protein (CREB) is a cellular 
transcription factor that binds to specific DNA sequences, thereby controlling the expression 
of certain genes (35, 36); with BDNF being one of the genes controlled by CREB transcription 
factor (36). CREB is responsible for various functions in different effector organs; some of its 
functions which have been studied concern the brain and the progression of neurodegenerative 
diseases (36, 37).  Recent clinical studies have implicated CREB in signal pathways related to 
the pathogenesis and treatment of  MDD (35). Studies have shown that the expression and 
functions of CREB are regulated by chronic antidepressant therapy and which is mediated by 
the expression of CREB in the hippocampus producing antidepressant-like effects, in 
behavioral models of depression (38, 39).  Furthermore, post-mortem studies indicate that 
CREB levels are increased in subjects taking antidepressants at the time of death and decreased 
in the cerebral cortex of depressed patients (39).  These findings shows that downregulation of 
CREB could contribute to the pathophysiology of depression and that upregulation of it could 
contribute to the therapeutic response (38). 
1.4.  Prevalence of depression in Sub-Saharan African countries 
Statistical data regarding the prevalence rates of MDD in Sub-Saharan African countries is 
very scarce and inadequate (40, 41).  Given the poor socioeconomic conditions of large 
segments of the population in many African countries, the prevalence of mental illness is 
expected to be high; with no exception to South Africa (40).  Several factors such as racial 
discrimination, high rates of poverty, political violence, gender inequality, high crime rates and 
unpredictable acute injuries from mining to miners, their families and communities all suggest 
that majority of the South African population may be at high risk of developing MDD or other 
psychiatric disorders (40, 42).  The sudden increase in suicidal rates across Southern African 
individuals has indeed confirmed that a large percentage of the population is living with 
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psychiatric disorders and are not receiving proper pharmaceutical or psychological 
interventions (43).  Limited data on prevalence rates of mental disorders in South Africa 
demonstrates that critical aspects of mental health are not being prioritized and also not given 
the attention they require; as a result, affected individuals remain neglected (43).  The 
negligence of mental health aspects has resulted in grave consequences where more than 100 
mental health patients have lost their lives at Life Esidimeni  Life Healthcare in the Province 
of Gauteng in South Africa between 2015 and 2016 (43).  Current studies that have been 
conducted used clinic attendance as a recruitment method, hence introducing a potential bias 
where members of the population who do not seek medical assistance or are unaware of their 
mental health status are not counted (41).  A study by Tomlinson et al., (2009) in a small rural 
settlement in South Africa found an MDD prevalence rate of 9.7% among a population of 4351 
adults South Africans of all racial groups (41).  Due to limited psychopathological data, there 
is a great need to promote mental health and depression awareness as a significant health policy 
objective and increasing efforts to identify and treat depressive disorders.  Figure 5 shows 
prevalence of diagnosed clinical depression around the world. 
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Figure 5: Depression rates around the world with the African continent, showing the high prevalence of the 




1.5.   MDD treatment using antidepressants 
Identifying and treating depression is vital to the care of patients living with depressive disorder 
(44).  Where antidepressants serve as a first-line treatment for moderate and severe depression 
regardless of environmental factors and depression symptom profile (44-46), this was observed 
in about two out of three outpatients with the current depressive disorder to receive 
antidepressant treatment (45, 47).  In addition to treating the various types of depression, 
antidepressants are widely used in the treatment of depression, anxiety, eating disorders, 
phobia, obsessive-compulsive disorder, bipolar disorder and substance dependence (45).  The 
medication is usually prescribed for depression of any severity of symptoms that have persisted 
for two years or more with all medication being considered equally effective; therefore, most 
clinicians select an agent-based upon its side effect and safety profile (44).  The antidepressants 
are given at its therapeutic dose for 4 6 weeks before determining whether it is effective or not 
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and its often based on a long term treatment, which results in many common side effects,  these 
include nausea, fatigue and drowsiness, weight gain, blurred vision and sexual dysfunction (44, 
47, 48).  There are various types of antidepressants, however only the following clinically 
prescribed drugs will be discussed; Tricyclic Antidepressants (TCAs), Monoamine oxidase 
inhibitors (MAOIs) and Selective serotonin reuptake inhibitors (SSRIs). They are mainly 
discussed since they are the first-line treatment clinically prescribed and have been widely 
available for over half a century (49).  TCAs and MAOIs have been predominantly used from 
the 1950s till the1980s prior to the first introduction of the SSRIs (49). 
1.5.1.  Tricyclic Antidepressant (TCAs) 
Tricyclic antidepressants were the first drug class used to treat depression and dominated 
treatment plans until the introduction of SSRIs in the 1980s and 1990s (50, 51).  Tricyclic 
antidepressants are classified based on their structure with three benzene rings fused together, 
mainly due to its unknown mechanism of action at the time of discovery (50, 52).  Therefore, 
TCAs are classified differently from other antidepressants, which are classified according to 
their mechanism of action (50, 52). TCAa have a different pharmacological profile with 
substantial pharmacological action at two reuptake transporters and three receptor proteins (50, 
51); these include, a serotonin reuptake inhibitor, a norepinephrine reuptake inhibitor, a 
dopamine reuptake inhibitor, an anticholinergic-antimuscarinic drug and an 1-adrenergic 
antagonist (50, 52).   They carry out their therapeutic effects by blocking the reuptake pumps 
of serotonin and norepinephrine, resulting in increased concentrations of serotonin and 
norepinephrine in the synaptic cleft, which alleviate the symptoms of MDD (50-52).  However, 
their adverse side effect profile limits their use, some side effect includes dizziness, memory 
impairments, drowsiness, decreased blood pressure, seizures and fatal if overdosed (50-55). 
Approximately 81% of deaths that occur in MDD patients are caused by TCA overdose  (50-
52, 55).  Thus, TCAs are prescribed or reserved as a second-line treatment drug for the 
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treatment of severe and unresponsive depression, such as melancholic depression (50, 55).  
Figure 6 shows some of the most commonly prescribed TCAs due to the efficacious 
therapeutic effects in the treatment of MDD. 
   
Figure 6: Common TCAs (a) Amitriptyline and (b) Imipramine. (Created by the author using ChemDraw 
Professional 17.1). 
 
1.5.2.  Monoamine oxidase inhibitors (MAOIs) 
 Clinical data shows that patients with MDD have symptoms that reflect changes in brain 
monoamine neurotransmitters, precisely serotonin, norepinephrine and dopamine (12).  
Patients with depression show high levels of the enzyme monoamine oxidase A (MAO-A) 
levels in brain regions, such as the hippocampus and prefrontal cortex (56).  MAO-A enzyme 
is mainly responsible for the catalysis of the oxidative deamination of biogenic monoamines, 
a significant step in their synthesis (57). MAO-A limits the levels of monoamine 
neurotransmitters (serotonin, noradrenaline and dopamine) (56, 58).  Positron emission 
tomography (PET) imaging has shown that higher MAO-A densities in the brain may 
contribute to the recurrence of depressive symptoms, signifying that inhibition of MAO-A may 
be an essential therapeutic intervention to prevent the recurrence of depression (56, 59).  
Monoamine oxidase-A inhibitors (MAOIs) were the first to be used as antidepressants and 
found to be active mainly for treatment-resistant depression (TRD) (12, 56).  Monoamine 
oxidase-A inhibitors exhibit their effects by preventing the deamination of MAO-A in the brain 
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and body, thus enhancing central nervous system monoamine levels (59).  However, their 
consumption has been reduced due to the severity of the adverse effects they have on central 
nervous system and peripheral organs; furthermore, reports of liver toxicity and in some cases, 
death resulted in reduced prescription of  MAOI's (12, 56). Moreover, their reduced  
consumption is due to dietary restrictions, as they tend to interect with other  drugs and food 
(tyramine reactions) (60).   Figure 7 shows candidate examples of  MAOIs. 
 
Figure 7: Examples of candidate MAOIs (a) Myricetin, (b) Brofaromine, and (c) Iproniazid. (Created by the 
author using ChemDraw Professional 17.1). 
 
1.5.3.  Selective serotonin reuptake inhibitors (SSRIs) 
SSRIs are usually used as first-line therapy for treating MDD in both adults and children (5, 
61, 62).  SSRIs are increasingly being used due to their superior tolerability, safety profiles and 
their potential for improved medication compliance with once-a-day dosing schedules relative 
to other antidepressants, such as MAOIs and TCAs (61, 63).  Thus MAOIs and TCAs are 
primarily reserved for moderate and severe MDD and SSRIs for milder forms of MDD (63).  
Furthermore, SSRIs are regularly used for maintenance therapy to prevent patient relapse (5).  
Although SSRIs are considered as the first-line treatment for MDD, only 50% of patients 
respond to the initial treatment, and even fewer patients achieve remission (64).  Thus, a 
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stepwise clinical treatment approach is often exercised in the setting of SSRIs non-responsive 
patients to shift to a second antidepressant with an alternate mechanism of action (64).  
Commonly used SSRIs for treatment of MDD include sertraline (SERT) and paroxetine 
(Figure 8) (13). 
 
Figure 8: Common SSRIs (a) Sertraline and (b) Paroxetine. (Created by the author using ChemDraw 
Professional 17.1). 
 
1.5.4.  Alternative pharmacological therapy 
Serotonin receptor Antagonists with serotonin reuptake Inhibitors (SARI) exhibit their 
therapeutic effects by moderately antagonising serotonin receptors with a weak serotonin 
reuptake transporter (SERT) inhibition. Hence, their primary pharmacodynamic effect and 
mechanism of action are not due to SERT inhibition (50). Typical SARIs include nefazodone, 
trazodone, and vortioxetine (50). Selective Norepinephrine Reuptake Inhibitors (NRIs) 
antidepressants are predominantly used for the treatment of MDD; however, they are also used 
for panic disorders, such as narcolepsy, bulimia, nervosa, and treating therapy-resistant 
pediatric nocturnal enuresis (50).  Common NRIs include Reboxetine and atomoxetine.  SARI 
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and NRIs have common side effects, such as SSRI-induced akathisia and sexual dysfunction 
(50). 
Figure 9 shows a proposed model which illustrates the range of activity of antidepressants 
highlighting their positive and negative effects (17, 65).  From the Figure 9, it can be deduced 
that use of norepinephrine/serotonin antidepressants can alleviate negative symptoms such as 
anxiety, fear and irritability, which are the hallmarks of depression (17, 65). In contrast, 
dopamine/norepinephrine antidepressants are shown to be more efficacious in treating 
depressive symptoms associated with the loss of positive affect such as loss of motivation, 
interest and pleasure (65).  However, the latter drugs require chronic therapy to produce their 
desired clinical effects in MDD patients and hence more efficient, and rapid antidepressants 
are needed to provide more acute relief. 
 
Figure 9: A Proposed model which shows the range of activity of antidepressants highlighting symptoms of 
positive and negative effects. Reprinted from Open Source literature (65). 
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1.6.  Ketamine 
Ketamine (RS-2-2-Chlorophenyl-2-methylamino cyclohexanone) is a racemic mixture that 
contains equal amounts of optical isomers that have nearly identical pharmacokinetic 
properties; however, possess different pharmacodynamic effects (66).  Ketamine is a derivative 
of phencyclidine (PCP), and it was first administered to human volunteers in the 1960s as a 
human anesthetic drug (67-69).  Due to its solubility in water and lipids, ketamine can be safely 
administered through multiple routes, such as intramuscular (IM), oral, rectal, subcutaneous, 
intravenous (IV) and epidural (70).  Ketamine was primarily used for anaesthetic induction and 
is defined as a dissociative hypnotic dut to the cataleptic state of involuntary movement, 
maintenance of spontaneous respirations, profound analgesia, and unresponsiveness to surgical 
stimulation achieved with induction dose (69).  The United States Food and Drug 
Administration (US FDA) officially approved ketamine as an anaesthetic in 1970 (67).  Today 
ketamine is being repurposed and is being used off-label as an adjunct of multimodal analgesia 
(acute pain and chronic pain), and most recently as an antidepressant in the treatment of MDD 
(67, 71, 72).  However, ketamine has some undesirable effects ranging from dissociative and 
psychotomimetic effects, memory and cognitive impairment, and direct and indirect peripheral 
effects (71).  Figure 10 shows the racemate structure of ketamine. 
 
Figure 10: Structure of racemate Ketamine. (Created by the author using ChemDraw Professional 17.1) 
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1.6.1.  Pharmacodynamic effects of ketamine as an antidepressant 
Clinical studies have shown that despite the wide range of antidepressants available, 
approximately one-third of MDD patients do not to respond to first-line antidepressants 
regardless of adequate dosage and duration (3).  Thus, placing an urgent need to develop novel 
and efficacious drugs to treat depression.  Ketamine, a non-competitive glutamate N-methyl- 
D-aspartate  receptor (NMDAR) antagonist, has recently become a focus of research for its 
antidepressant effects which occur within hours following administration of subanesthetic 
doses (3, 73).  Ketamine has demonstrated fast-acting effects in patients treatment of patients 
with treatment-resistant depression (TRD) (74). Evidence of ketamine's antidepressant actions 
dates back to the 1970s, where preclinical studies have shown that ketamine exhibited similar 
effects to those observed following administration of classic antidepressant drugs (71).   
Ketamine exerts its effect based on a hypothesised direct inhibition of the NMDAR, which 
represents a target for faster-acting antidepressant actions (75).  The following are the 
hypothesised ketamine s mechanisms of action in the treatment of depression during NMDAR 
inhibition (a) disinhibition of glutamate release, (b) blockade of extra-synaptic NMDARs, (c) 
blockade of spontaneous NMDAR activation, (d) the role of the ketamine metabolite (2R,6R)-  
hydroxynorketamine (HNK) and (e) inhibition of NMDAR- dependent bursting activity of 
lateral habeluna neurons. (75, 76). These hypothesised mechanisms are summarised below and 
illustrated in figure 11. 
(a) Disinhibition of glutamate release: 
According to the disinhibition hypothesis, ketamine selectively block NMDARs expressed on 
GABAergic inhibitory interneurons, leading to a disinhibition of pyramidal neurons and 
enhanced glutamatergic firing (75). The Induced released glutamate then binds to and activates 
post-synaptic -amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors (AMPARs) 
which subsequently results in enhanced brain-derived neurotrophic factor (BDNF) release (75, 
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76). Activation of the tropomyosin receptor kinase B (TrkB) receptor and promotion of protein 
synthesis occurs through activation of the mechanistic target of rapamycin complex 1 
(mTORC1) (75, 76). 
(b) Blockade of extra-synaptic NMDARs: 
Ketamine is suggested to selectively block/inhibit extra-synaptic GluN2B-containing 
NMDARs activated by low levels of ambient glutamate which are regulated by the glutamate 
transporter-1 that is located on the astrocytes (75, 76).  This subsequently leads to the de-
suppression of mTORC1 function, which then induce protein synthesis (75-77).  
(c) Blockade of spontaneous NMDAR activation: 
This hypothesis insinuates that ketamine hinders NMDAR-mediated neurotransmission, which 
leads to the inhibition of the eukaryotic elongation factor 2 kinase (eEF2K) activity, therefore 
preventing the phosphorylation of its eEF2 substrate (75). This effect then leads to an 
improvement or enhanced BDNF expression (75).  
(d) Ketamine hydroxynorketamine (HNK) metabolites: 
It is hypothesised that ketamine exerts NMDAR inhibition-independent antidepressant actions 
via the action of its metabolites, (2R,6R)-HNK and (2S,6S)-HNK (71). Ketamine is metabolised 
to HNKs after administration, and the HNK metabolites act to promote AMPAR- facilitated 
synaptic potentiation (71, 75). 
 (e) Inhibition of NMDAR-dependent burst firing activity of lateral habenula 
(LHb) neurons:  
It is proposed that ketamine decrease excessive NMDAR-dependent burst firing activity of 
LHb neurons that is said to be associated with the depressive symptomatology (78). The 
observed mechanisms of ketamine are not mutually exclusive; hence, they may act 
complementary in bringing about the antidepressant actions of the drug as all hypotheses 
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suggest acute changes in synaptic plasticity, which leads to the sustained strengthening of 
excitatory synapses which are necessary for antidepressant responses (75). 
 
Figure 11: Proposed mechanisms of action for ketamine as an antidepressant. Reprinted from Open Access 
Literature (79). 
 
1.7.  Esketamine nasal spray for severe depression 
Currently, there is an approved treatment for the emergency management of patients with a 
major depressive disorder who are assessed to be at imminent risk for suicide (80). Several 
clinical studies have demonstrated the robust and rapid therapeutic effects produced by 
ketamine at subanaesthetic dosages (81).  However, most clinical studies that evaluated the 
anti-depressive effects of ketamine have been using its racemic mixture (81).  The racemate of 
ketamine is comprised of R-(-)-ketamine enantiomer (Arketamine) and the S-(+)-ketamine 
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enantiomer (Esketamine) as shown in Figure 12.  The ketamine racemate mixture can be 
separated by using chromatographic and electrophoretic techniques (82).  Recent studies have 
shown that the analgesic potency of the S-(+)-ketamine is approximately two times higher than 
that of  ketamine (racemate), subjects also presented with a lower incidence of impairment in 
concentration and memory with S-(+)-ketamine than with the racemate, depicting that                 
S-(+)-ketamine is better tolerated than the racemic ketamine (81).  Furthermore, studies have 
shown that S-enantiomer has approximately a 3-4 fold higher affinity for NMDARs than          
R-(-)-ketamine (83, 84).  However, some studies have shown that R-(-)-ketamine has higher 
potency and more prolonged antidepressant effect than S-(+)-ketamine in animals, specifically 
rodents (83, 85).  Thus, suggesting that NMDARs may not play a significant role in the 
sustained anti-depressive effects of ketamine (85).         
 
Figure 12: Enantiomers of ketamine (a) Esketamine and (b) Arketamine. (Created by the author using ChemDraw 
Professional 17.1). 
Esketamine (S-(+)-ketamine) has most recently been approved for treating depression; it has 
been recently developed by Janssen Pharmaceuticals (United States) and approved by the 
United States Food and Drug Administration (US FDA) in March 2019 (86).  The recently 
approved antidepressant makes use of an intranasal formulation, due to the instant onset of 
antidepressant effects observed in patients with TRD as early as 2 hours and 24 hours after 
single-dose of the intranasal formulation (80, 81, 84, 86).  The first results that were published 
using the intranasal formulation were from a randomised, placebo-controlled, multiple-dose 
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study, which comprised of  67 participants with TRD, the study showed a dose-response 
relationship, favouring the highest intranasal dose of 84 mg (86).  Recent clinical trials 
examined the use of Esketamine in individuals with MDD who have not responded to 
traditional antidepressant treatment, the primary outcome of the study showed a greater 
decrease in depression, with a significant difference from other patients receiving a traditional 
antidepressant treatment (86).   
1.7.1.  Esketamine usage guidelines 
The approved esketamine  nasal spray is only available through a controlled distribution system 
under a risk evaluation and justification strategy, according to the US FDA (87). Esketamine s 
associated adverse side effects includes: elavated blood pressure, dizness, sedation and 
psychotomimetic reactions (88). This means that both the patient and a physician must sign a 
patient enrolment form that states that the patient understands that s/he needs to have help 
safely leaving doctor's office and that the patient will not drive or operate heavy machinery the 
day after the use of the drug (87). Furthermore, Esketamine can only be taken under medical 
supervision (Doctor s office), although a patient would be able to self administer the drug after 
a doctor has demonstrated how to use it; hence ketamine remains the most readily available 
treatment of depression (87). 
1.7.2.  Esketamine Mechanism of Action 
While the exact mechanisms underlying the anti-depressive effects of Esketamine remains 
unclear, the rapid antidepressant effects are said to occur via the blockage of NMDARs located 
on inhibitory interneurons, hence having a similar mechanism of action as racemate ketamine 
(85). This blockage results in disinhibition of pyramidal cells, which then leads to a burst of 
glutamatergic transmission (85). It is understood that the elevated increase of glutamate release 
activates AMPARs, as AMPAR antagonists block the antidepressant effects of ketamine and 
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its enantiomers (85). Collectively, AMPAR activation plays a substantial role in the 
antidepressant effects of ketamine and its enantiomers. 
ANALYTICAL TECHNIQUES 
1.8.  Liquid Chromatography-Mass Spectrometry (LC-MS) 
Chromatography is used to separate complex mixtures using the differences in the distribution 
coefficient between mobile and stationary phase (89, 90).  Chromatography is separated into 
groups according to the state of the mobile phase, and it can be gas chromatography (GC), 
liquid chromatography (LC) or supercritical fluid chromatography (SFC) (89).  Liquid 
chromatography uses a mobile phase in which the analytes are miscible (91).  The LC 
separations are predominantly carried out in reversed-phase chromatography, where the mobile 
phase is polar then the stationary phase (non-polar) and the more polar analytes elute more 
rapidly than, the less or non-polar ones (91).  A separation comprising a mobile phase of 
constant composition is referred to as an isocratic elution, while that in which the composition 
of the mobile phase is gradually changed is called gradient elution (91).  Mass spectrometry 
(MS) is an analytical technique that measures the mass-to-charge (m/z) ratio of ionic species of 
an analyte (92).  MS is broadly used in the pharmaceutical field due to favourable 
charactersistcs such as high selectivity, high sensitivity, and capability of providing 
information (relative molecular mass and structural characteristics) (89).  Coupling of MS to 
chromatographic techniques has always been advantageous due to the sensitive and highly 
specific nature of MS detectors compared to other traditional chromatographic detectors (93).  
However, an interface is required to couple the two techniques together due to their 
incompatibilities; with its prime purpose being the removal of the chromatographic mobile 
phase and the generation of ionic species that can be detected using the mass spectrometer (91).  
The efficient coupling of MS with liquid chromatography (LC-MS) in this study was achieved 
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employing electrospray ion (ESI) sources which have generated a high drive in the 
development of  LC-MS-based assays to be used in clinical chemistry (90).  
LC with tandem MS (LC-MS/ MS) is now frequently used in clinical investigations (Figure 
13), such as metabolic disorders, endocrinology, and therapeutic drug monitoring (90), this is 
mainly due to  LC-MS being capable of both qualitative and quantitative analyses of complex 
biological matrices (89). 
 
Figure 13: Schematic block diagram illustrating the basic workflow of a typical LC-MS system. (Created by Author). 
 
1.8.1.  Components of High-Pressure Liquid chromatography (HPLC) 
A basic HPLC system comprises of the following components: binary/quarternary pump, an 
automated sample injector, column and detector. 
1.8.1.1.  Pump 
The pump plays a role of delivering a high volume of mobile phase at a stable flow rate between 
10 ul/min and 2 ml/min. It comprises of inert material towards solvents (91, 92).  There are 
three main types of pumps: reciprocating, syringe and constant pressure pumps (92). These 
pumps are capable of delivering solvent at a constant composition or a changing composition. 
1.8.1.2.  Autosampler  
The sample injector introduces a specified volume of sample into a flowing mobile phase liquid 
stream in the chromatographic system (91, 92).  An injectable amount of sample volume range 
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injectors). Automatic injectors are more user-friendly, accurate and precise, as compared to 
manual injectors (92). While injecting the sample into the system, the mobile phase is pumped 
at the chosen flow rate through the valve to the column to keep the column in equilibrium with 
the mobile phase and uphold chromatographic performance (91). 
1.8.1.3.  Columns or stationary phase 
Commonly used HPLC columns contain a silica stationary phase fused with hydrocarbon 
chains, with various chemical modifications determining the polarity of the column (91, 92). 
Columns range between  50 to 300 mm in length, with particle sizes ranging between 5 to 3.5 
m and 3 m internal diameter; and they consist of octyl (C8), octadecyl (C18), amino, cyano,  
and phenyl packing material (92).  The nature of the compound being separated determines the 
type of column used (92). 
1.8.2.  Basic Components of a Mass spectrometry 
The MS consist of three significant components, ionisation source and interface, a mass 
analyser and detector (92, 93). 
1.8.2.1.  Ionisation source and interface 
The mixture of components (liquid) is transferred into the ion source of MS, where ion source 
is exposed to high vacuum (92).  Due to the difference in the pressure, it is challenging to 
vaporise the liquid drops without losing a mixture of components; thus, interfaces are used  
(92).  There are several ionisation sources and interfaces, such as Electrospray Ionisation (ESI), 
Matrix-assisted laser desorption ionisation (MALDI, Atmospheric pressure photo Ionisation 
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Electrospray Ionisation  (ESI): 
ESI is the universally used ion source developed by John Bennett Fenn in 1980s (92, 93).  ESI 
works well with moderately polar molecules; hence it is well suited for the analysis of a wide 
range of biological materials (93).  Liquid samples are pumped across a metal capillary  
maintained at 3 - 5 kV and nebulised at the tip of the capillary to produce a fine aerosol of 
charged droplets as illustrated in Figure 14 (94). The charged droplets undergo rapid 
evaporation by the assistance of heat and dry nitrogen where they are continuously reduced in 
size until they become unstable upon reaching Rayleigh limit (95, 96). When the charge 
exceeds the Rayleigh limit, the droplet undergoes Coulomb explosion, where it dissociates, 
leaving a stream of positively charged ions, as seen in Figure 14 (96, 97).  The remaining 
electrical charge on the droplets is transferred to the analytes, which are ionised then 
transported into the high vacuum of the MS via a series of small apertures and focusing voltages 
(90, 92, 93).  The ions (postive/negative) are then detected through operation of the ion source 
and ion optics (93).  LC-MS  with ESI is largely used in biological research for medical analysis 
(92). 
 
Figure 14: Electrospray ionization source principle of ion generation. (Adapted from 
https://commons.wikimedia.org/w/index.php?curid=72802277). 
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1.8.2.2.  Mass Analyser 
Mass analyser is responsible for separation of ionized according to their mass to charge (m/z) 
ratio; use of mass analyser depends on its speed, time, rate and its reaction (93).  MS allows 
for the analysis of multianalyte panels using a single method, which saves time  and resources 
(90).  Several technologies available allow for the combination of ion source and MS detectors 
to detect ions, mainly quadrupole, time of flight (TOF), and hybrid analyzers (90). 
Quadrupole Mass Analyser: 
The quadrupole analyser primarily contains four set of parallel metal rods (Figure 15); where 
the combination of constant and alternating voltages allows the transmission of a narrow band 
of m/z values along the axis of the rods (93). Voltage alternation with time allows scanning 
across a range of m/z values,  which results  in a mass spectrum (93).  Most quadrupole 
analysers can measure above 4000 m/z with scan speed going up to 1000 m/z per sec, and it 
can allow monitoring of a specific m/z value; achieved by stepping the voltages (93).  This 
technique is advantageous because it improves the detection limits of desired analytes; this is 
achieved by direct scanning of to specific ions instead of scanning across ions that are not 
produced by the analyte. Furthermore, ions can undergo fragmentation by collisions with an 
inert gas (nitrogen or argon)  in a process know as collision-induced dissociation (93).  
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Figure 15: Schematic diagram of quadrupole mass analyzer. Adapted from open source: 
http://www.bris.ac.uk/nerclsmsf/techniques/gcms.html 
 
1.8.2.3.  Detector 
Detector is an essential part of MS that produces a current that is proportionate to the number 
of ions striking it (92). The formed ions pass from the analyser to the detector for detection and 
transformation into a digital signal that can be analysed (92).  
 Point Ion Collectors Detector:  The ion collector are placed at a predetermined point in MS, 
and focused on the detector positioned at a single point; the data is recorded when the electric 
current flow caused by the arrival of ions is proportional to the ions arriving at point ion 
detector (92).  
Array Detector: array detector is a collection of point collectors placed in detector where mass 
to charge (m/z) of ions are separated and are recorded using point ion collector (92). Spatially 
separated ions with the mass range are simulteneously detected at the same time in array 
detector (92). 
Electron multiplier detector: this is the most common MS detector, due to its high signal 
amplification and relatively low cost (94, 98). Most multipliers are cone-shaped and can 
amplify the relatively weak ion beam signal to the order of 105 to 106 (94, 98).  It is made of 
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glass that is coated with semiconductor substance that emits secondary electrons when 
impacted by charged particles (98).  Ions from the mass analyser are fast-tracked to the outer 
end of the multiplier where they colllide the multiplier surface, resulting in emission of several 
electrons, and these electrons are then attracted further into the multiplier, undergoing further 
collisions with the surface (94, 98). This results in the ion beam leaving the mass analyser to 
be converted into a cascade of electrons (current) is digitized in an analogue-to-digital 
converter and sent to a computer system where the mass spectrum is generated (98). 
 
1.9.  Quantitative real-time polymerase chain reaction (qPCR) 
Quantitative real-time polymerase chain reaction (qPCR) is a reliable modern quantitative 
nucleic acid technique that is widely used for gene expression analysis (99). It is primarily 
employed in several vital areas, including diagnosis of infectious diseases, human genetic, 
microbiology and biotechnology analysis (99). qPCR enables simultaneous analysis of 
different samples from as little as one cell in the same experiment, and it has high sequence 
specificity, increased sample throughput, cost-effective and highly accurate (99-101). 
Furthermore, it does not require post-amplification processing (99). The accuracy of qPCR is 
determined by several factors, such as variability in efficiencies of reverse transcription and 
PCR reaction (101). During gene expression analysis, number of variables are taken into 
considering when using qPCR; this includes: quality of ribonucleic acid (RNA), the efficiency 
of amplification, starting material, and suitable reference gene which serves as an elementary 
prerequisite for reliable results (99).  During gene expression analysis by qPCR, the messenger 
RNA found in the sample is copied to complementary DNA by reverse transcription (RT) 
(102). The RT step is crucial for ensuring accurate quantification and higher sensitivity; Figure 
16 shows a summarized protocol of a typical qPCR experiment (102). 
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Figure 16: Scheme of the QRT-PCR analysis process. Adapted from Open-Source Literature (102).  
 
1.10.  Motivation for the study 
Researchers have established that deficits in vital neurotransmitter networks between specific 
neurons in the brain may contribute to the development of depression (17). Ketamine, an 
NMDAR antagonist and an AMPAR stimulator have been as an off-label in the management 
and treatment of MDD until the US FDA approved esketamine  nasal spray as a treament for 
MDD (73, 86). Ketamine has been used as an offlabel drug due to its ability to stimulate the 
generation of new receptors and synaptic pathways in the brain, which helps patients regulate 
their mood, sleep better, and experience better focus .  Ketamine works by altering and 
rebalancing the excitatory and inhibitory system (glutamate and GABA) to stimulate new 
synaptic connections, better memory, and improved brain plasticity (103). However, there are 
limited published studies that demonstrate the direct relationship between ketamine, brain 
neurotransmitters levels, and gene expression in the management of MDD. This study will 
contribute to the understanding of the role of Ketamine in the treatment and management of 
MDD. 
1.12.  Aims and objectives 
The research aims to study the pharmacodynamic effects of ketamine in the brain by assessing 
changes in neurotransmitter levels using LC-MS/MS and to investigate the effect of ketamine 
Page | 29  
 
in transcription factor cyclic AMP response element-binding protein (CREB) and the 
neurotrophin brain-derived neurotrophic factor (BDNF) in treatment of depression using 
quantitative real-time polymerase chain reaction analysis. 
Objectives: 
1. To develop and optimise an LC-MS/MS method for the simultaneous quantification of 
neurotransmitters (serotonin, norepinephrine, dopamine, glutamate and -aminobutyric 
acid) in the brain homogenates of rodents treated with ketamine. 
2. To establish the effects of ketamine on gene expression of BDNF and CREB in the 
brain of rats treated with ketamine. 
3.  To determine the anti-depressive mechanism based on the pharmacodynamic changes 
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Abstract 
Background: Ketamine has recently been approved for the management and treatment of 
major depressive disorder (MDD); however, its mechanism remains unknown.  In this study, 
we examined the pharmacodynamic effects of Ketamine in rat brain by assessing changes in 
neurotransmitter levels and investigating the links between Ketamine and the transcription 
factors, brain-derived neurotrophic factor (BDNF) and cyclic adenosine monophosphate 
(cAMP) response element-binding protein (CREB). 
Methods: Twenty-one healthy male Sprague-Dawley (SD) rats were administered 15 mg/kg 
of Ketamine intraperitoneally at 0 (control), 5, 15, 30, 60, 120, and 240 minutes (n = 3 per time 
point). Liquid chromatography tandem mass spectrometry (LC-MS/MS) was employed to 
assess neurotransmitter levels in rodent brain samples and the gene expression of BDNF and 
CREB was determined using quantitative polymerase chain reaction (qPCR). 
Results: Ketamine reached Cmax (351.33 ± 108.38 ng/mL) in the brain at 5 minutes post-
administration.  At Ketamine s Tmax, Glutamate and gamma-aminobutyric acid (GABA) 
showed a significant increase (p = .005 and p = .007, respectively) compared to the control and 
other monoamine neurotransmitters in the brain. At 5 minutes, BDNF showed significant (p < 
.0001) downregulation of 0.96-fold compared to the control, while CREB showed no 
significant changes.  At low Ketamine concentrations (0.428 ± 0.042 ng/mL), BDNF showed 
an increase of 0.25-fold compared to 5 minutes (Ketamine s, Cmax). 
Conclusion: The findings show that ketamine may alleviate depression by altering the 
glutamatergic system which occurs via the disinhibition of glutamate release. This enhances 
central nervous synaptogenesis and balances the deficit of other neurotransmitters and proteins 
associated with the pathophysiology of depression. 
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2.1.  Introduction  
Major depressive disorder (MDD) is one of the most common psychiatric disorders affecting 
over 264 million people worldwide (1, 2); World Health Organization s (WHO) estimated 
demographics have shown that approximately 1 in every 23 people in the world suffers from 
depression (3).  Depression has led to severe socioeconomic and health consequences, making 
MDD the costliest mental disorder worldwide (2, 4, 5), with it projected to become the most 
significant contributor to the global disease burden by 2030 (3). Cognitive and affective deficits 
combined with anhedonia for more than two weeks are the main symptoms of MDD (6, 7).  
Several clinical studies have linked various factors to the underlying pathophysiology of 
depression; these factors include brain monoaminergic, GABAergic, and glutamatergic 
neuronal dysfunction (8-12).  This has led to the monoamine hypothesis of depression, which 
predicts that the underlying pathophysiologic basis of depression is a depletion in the levels of 
dopamine (DA), serotonin (5-HT) and norepinephrine (NE)  in the central nervous system (13); 
however, depression remains a multi-etiological disease.  
 A similar hypothesis was developed regarding the transcription factors, brain-derived 
neurotrophic factor (BDNF) and cAMP response element-binding protein (CREB), which 
states that loss of BDNF and CREB plays a significant role in the pathophysiology of 
depression and that restoration of their activities may represent a critical target underlying the 
effectiveness of antidepressants (14, 15). This was supported by various studies that assessed 
neurotransmitter alterations associated with MDD; these studies demonstrated that 
neurotransmitters such as gamma-aminobutyric acid (GABA), glutamate (Glut), DA, 5-HT and 
NE were deficient in both the depressed rodent and human brain (11, 16-20).  Furthermore, 
clinical studies have shown reduced BDNF and CREB levels in the hippocampus in post-
mortem samples taken from MDD patients who have committed suicide (21).  Many of the 
currently available antidepressants are known to potently alter the central monoaminergic 
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system and increase BDNF and CREB expression in the brain (15, 22-24). However, they  
require chronic therapy (prophylactic treatment) to produce their desired antidepressive effects 
which increase the risk of severe adverse effects; hence more efficient and rapid-acting 
antidepressants are needed to manage the disorder. 
Some clinical studies have shown that Ketamine possesses effective, rapid antidepressant 
effects as early as 2-24 hours against treatment resistant MDD (25-27).  Ketamine, a widely 
used anaesthetic agent, has been used as an off label treatment for MDD until March 2019, 
when the United States Food and Drug Administration (US FDA) approved Esketamine (the 
S-enantiomer of Ketamine) in a nasal spray formulation for the management of treatment-
resistant MDD (28).  However, Esketamine use is well controlled and it is only made available 
under a strict risk evaluation and mitigation strategy due to its adverse side effects (28). In 
addition, the cost of this intranasal treatment is high and maybe inaccessible for patients in low- 
and middle-income countries (29).  The high cost is associated with healthcare cost and 
logistics due to availability under healthcare supervision and must be imported to other 
countries.  Hence, Ketamine remains the most readily available efficacious antidepressant in 
the treatment of severe depression, treatment-resistant depression, and MDD. Currently, there 
are limited studies investigating the direct relationship between the expressions of BDNF and 
CREB as well as brain neurotransmitter changes associated with Ketamine use for the treatment 
of MDD.   
This study therefore aimed to investigate the pharmacodynamic effects of ketamine in the brain 
by assessing changes in monoaminergic, glutaminergic and GABAergic neurotransmitter 
levels using liquid chromatography tandem mass spectrometry (LC-MS/MS). Further, the 
relationship between Ketamine and the expression of the transcription factors, CREB and 
BDNF was investigated using quantitative polymerase chain reaction (qPCR). These findings 
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will contribute to our understanding on the role of Ketamine in the treatment and management 
of MDD.  
2.2.  Methods and Materials 
2.2.1. Chemicals and Reagents 
All chemicals and reagents utilised in this study were of analytical grade: Serotonin (5-HT), (-
)-Norepinephrine (NE), Dopamine hydrochloride (DA), y-Aminobutyric acid (GABA), and L-
Glutamic acid monosodium were all sourced from Sigma-Aldrich (St. Louis, MO). Serotonin 
D4 hydrochloride, an internal standard for quality control, was purchased from Clearsynth 
(Mississauga, Canada).  Ketamine-HCL solution (100 mg/ml) was purchased from Fresenius 
Kabi Manufacturing (SA) Pty. Ltd, and LC-MS grade methanol (MeOH) was procured from 
Sigma Aldrich (Steinham, Germany). Analytical grade formic acid was purchased from Merck 
Millipore (Johannesburg, South Africa).  Discovery® DSC-18 solid-phase extraction (SPE) 
cartridge (wt. 100 g, volume 1 mL) was purchased from Merck, South Africa. Glyceraldehyde 
3-phosphate dehydrogenase (GAPDH), CREB, and BDNF primer sequences were purchased 
from Inqaba Biotec  (Pretoria, South Africa).  Water was purified using a Milli-Q water 
purification system (Bedford, MA, USA). All other chemicals utilised in this study were of 
analytical grade. 
2.2.2. Animals and Ethics  
The use of animals, including experimental procedures, handling and treatment were all 
approved by the University of Kwazulu-Natal Animal Research Ethics Committee (UKZN, 
AREC) with approval reference AREC/003/018M.  Twenty-one male Sprague-Dawley (SD) 
rats ranging from 120-130 g were sourced from the University of Kwa-Zulu Natal Biomedical 
Resource Unit (Durban, South Africa).  All animals were housed under appropriate ethical 
standards approved by the Biomedical Resource Centre in a well-ventilated room with 
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humidity control systems, a 12-hour light/dark cycle, ad libitum access to standard rat chow 
and water, and the recommended environmental enrichment. 
2.2.3. Drug administration and sample collection 
Twenty-one animals were administered a dose of 15 mg/kg body weight (bw) of Ketamine-
HCL via intraperitoneal (IP) injection per time point, with three animals serving as the control.  
The dose was based on a previous study conducted at the University of KwaZulu-Natal, 
Catalysis and Peptide Research Laboratory, which showed that IP administration of 
15 mg/kg.b.w of Ketamine-HCL exhibited more favourable brain drug delivery in order to 
produce maximum therapeutic concentrations when compared to other routes of administration 
(30). Animals (n = 3 per group) were euthanized by decapitation using a rodent guillotine at 0 
(control), 5, 15, 30-, 60-, 120-, and 240-minutes post Ketamine administration. Brain tissues 
were surgically removed post-termination, frozen gradually using liquid nitrogen, and stored 
at -80 °C until further analysis. 
2.2.4. Biological Samples 
Brain samples were weighed and cut into small pieces with a surgical blade before being 
homogenized using an OMNI tissue homogenizer (Kennesaw Georgia, USA) in ultra-pure 
water in a 1 g: 1 mL ratio. The homogenised samples were then stored at -80 C until further 
processing.  Brain samples for qPCR were stored ( 80 C) in Qiazol lysis reagent (500 µL; 
Qiagen, Hilden, Germany). 
2.2.5. LC-MS/MS Method 
Instrumentation: 
The liquid chromatography (LC) system used for analysis consisted of a Thermo Scientific 
Vanquish Ultra-High-Performance Liquid Chromatography (UHPLC) (Waltham, MA USA) 
coupled to Thermo Scientific TSQ Quantis Triple Quadrupole Mass Spectrometer (Waltham, 
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MA USA).  All the data obtained was analysed and processed using Thermo Trace finder 
General (4.1 SP5) and Thermo Scientific SII Xcalibur 1.3 (3.0.20389) software. 
Chromatographic conditions: 
Chromatographic separation was achieved using a Poroshell 120 EC-C18 (50 mm x 4.6 mm, 
2.7 µm) (Agilent Technologies, California, USA) with a gradient mobile phase composition 
consisting of 0.1% v/v Formic Acid in ultra-pure water (A) and 0.1% v/v Formic Acid in 
Methanol (B). The gradient elution was as follows: The gradient started with a 1 min pre-
injection equilibration step held at 15% B, then increased linearly from 15-70% B in 1 min, 
followed by a further increase to 95% B in 0.1 min, then held at 95% B for 4.4 min, followed 
by a decrease to 15% B in 0.1 min and finally held for 2.4 min at 15% B.  The flow rate was 
set at 0.800 mL/min, with an injection volume of 10 L and a total run time of 9 min. 
Mass spectrometric condition: 
Quantitative studies were conducted using Tandem MS (MS/MS) via a Heated Electrospray 
Ionization (H-ESI) interface in positive mode, with the following source parameters: spray 
voltage, 4.8 kV; sheath gas, 50 Arb. Unit; auxiliary gas, 15 Arb. Unit; sweep gas, 1.2 Arb. Unit; 
vaporizer temperature, 400 C; and ion transfer tube 325 C.  Other conditions, such as collision 
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137 Quantifier 14.55 78 9.473 
90.946 Qualifier 27.51 78 9.473 





87 Quantifier 13.41 30 9.473 
46 Qualifier 55 30 9.473 
85.875 Qualifier 15 30 9.473 
Glutamate 148.05 84.071 Quantifier 18.98 30 9.473 






152.054 Quantifier 10.23 79 9.473 
107.018 Qualifier 23.99 79 9.473 






159.982 Quantifier 10.23 30 9.473 
114.929 Qualifier 46.7 30 9.473 







164.020 Quantifier 10.23 192 9.473 
78.557 Qualifier 34.57 192 9.473 
118.042 Qualifier 26.49 192 9.473 
 
Ketamine 
238.1 124.989 Quantifier 47.23 85 9.473 
220.030 Qualifier 22.85 85 9.473 
162.911 Qualifier 31.65 85 9.473 
 
2.2.6. Sample preparation for LC-MS/MS analysis 
Samples for LC-MS/MS analysis were prepared by adding 100 µL of brain homogenate to 850 
µL of Methanol (MeOH), spiked with 50 µL of internal standard (10 µg/mL) and vortex mixed 
briefly. The mixture was then centrifuged at 10 000 x g for 10 minutes at 4 C.  The resulting 
supernatant was filtered through a DSC-18 SPE cartridge (wt. 100 g, volume 1 mL) and the 
eluent was collected in an autosampler vial. 400 µL of the SPE eluent sample was then dried 
or evaporated under a stream of nitrogen using a flow of 2 bars using Zipvap nitrogen 
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evaporator (Glass-Col, Terre Haute, USA). The dried sample was then reconstituted in 400 µL 
ultrapure water and vortex mixed for 30 seconds, before LC-MS/MS analysis 
2.2.7. RNA isolation  
RNA was extracted from brain tissues using Qiazol reagent (Qiagen, Hilden, Germany).  
Briefly, 100 PL brain homogenate was incubated overnight (-80 °C) in 500 PL Qiazol reagent. 
Thereafter, the samples were thawed at room temperature (RT) and chloroform (100 PL) was 
added. The samples were centrifuged (12 000 x g, 15 min, 4 qC) and the aqueous phase 
containing crude RNA was transferred to fresh 1.5 mL micro-centrifuge tubes. Isopropanol 
(250 PL) was added to the aqueous phase followed by overnight incubation at -80 qC.  The 
samples were then centrifuged (12 000 x g, 20 min, 4 qC) and the RNA pellets were washed in 
500 PL of 75 % cold ethanol.  The samples were further centrifuged (7 400 x g, 15 min, 4 qC) 
before discarding the ethanol and allowing the RNA pellets to air dry for 30 min at RT. The 
RNA pellets were resuspended in 15 PL nuclease-free water, followed by incubation at RT for 
3 min before RNA quantification. Quantification and purity of RNA samples was determined 
using the Nanodrop  2000 spectrophotometer (Thermo-Fisher Scientific, SA). The purity of 
the RNA was assessed using the A260/A280 absorbance ratios. All samples were standardized 
to a final concentration of 1,000 ng/µL.  
2.2.8. CREB and BDNF mRNA/gene expression 
Total RNA (1,000 ng/µL) was reverse transcribed into cDNA using the Maxima H Minus First 
Strand cDNA Synthesis Kit (Thermo-Fisher Scientific, California, USA) as per the 
manufacturer's instructions.  Thereafter, the mRNA expression of CREB and BDNF (See Table 
2 for primer sequences) was determined using the PowerUp  SYBR  Green Master Mix 
(Thermo-Fisher Scientific, California, USA) as per the manufacturer's protocol. The reaction 
was amplified using the Applied BioSystems ViiA 7 Real-Time PCR System (Thermo-Fisher 
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Scientific, California, USA) with the following cycling conditions: initial denaturation (95°C, 
8 min), followed by 40 cycles of denaturation (95°C, 15s), annealing (60°C, 40s), and extension 
(72°C, 30s). GAPDH was used as the housekeeping gene to normalize differences in mRNA 
expression. The data was analysed according to the methods described by Livak and 
Schmittgen (2001) and represented as a fold change relative to the control (31). 
Table 2: Primer sequences of CREB, BDNF, and GAPDH 
Gene Primer Sequence 
CREB Sense: 5'-CCAAACTAGCAGTGGGCAGTATATT-3' 
Anti-sense: 5'-GGTACCATTGTTAGCCAGCTGTATT-3' 
BDNF Sense: 5'-GAATTCATGACCATCCTTTTCCTTACTATG-3' 
Anti-sense: 5'-AAGCTTTCTTCCCCTTTTAATGGTCAG-3' 
GAPDH Sense: 5 -GGCACAGTCAAGGCTGAGAATG-3  
Anti-Sense: 5 -ATGGTGGTGAAGACGCCAGTA-3  
 
2.2.9. Statistical analysis 
Statistical analysis was carried out using GraphPad Prism 8.4.3. (GraphPad Software Inc., La 
Jolla, USA).  Statistical significance (p) was determined using the Holm-Sidak t-test method, 
with alpha = 0.05.  Each row was analyzed individually without assuming a consistent standard 
deviation (SD).  Results were expressed graphically as mean ± SD. A p < 0.05 was considered 
significant. Pharmacokinetic (pK) parameters were determined using STATA/IC 15.0 
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2.3.  Results 
2.3.1. Regulation of neurotransmitters by Ketamine 
At clinical doses, Ketamine is known to directly affect a wide range of brain neurotransmitters; 
hence, we investigated the pharmacodynamic effects of Ketamine on five major brain 
neurotransmitters associated with MDD at different time intervals (5, 15, 30, 60, 120, and 240 
min).  Ketamine levels were also quantified (for spectra and chromatograms: See Appendix) 
after administration of 15 mg/kg.b.w (IP) at each time interval (Fig. 17A). Ketamine reached 
its highest concentration (Cmax) in the brain at 5 min post-administration (351.33 ± 108.38 
ng/mL) (Table 3). At 15 min, Ketamine concentration significantly decreased by five-fold 
when compared to the drug concentration at 5 min post dosing (p = .050) (Fig. 17A).  From 15 
min, onwards Ketamine levels decreased gradually, as shown in Fig. 17A.   
Glut and GABA showed a similar trend with respect to their concentration changes post 
Ketamine administration (Fig. 17C and 17F).  At 5 min post administration of Ketamine both 
Glut and GABA were significantly increased (1167.98 ± 108.31 ng/mL, p = .005 and 1458.65 
± 82.70 ng/mL, p = .007 respectively) compared to the control group at 0 min (716.1 ± 92.41 
ng/mL, p > .9999, and 1097 ± 90.75 ng/mL, p > .9999 respectively) (Fig. 17C and 17F).  
Similarly, after 15 min, they were significantly increased (Glut: 1218.37 ± 212.39 ng/mL, p = 
.0198; GABA: 1619.70 ± 47.36 ng/mL, p < .001), respectively.  At 30 min, Glut (909.93 ± 
47.81 ng/mL, p = .0321) and GABA (1345.77 ± 157.68 ng/mL, p = .0771) were decreased 
when compared to the concentrations observed at 15 min and increased at 60 min.  A significant 
increase compared to the control (716.1 ± 92.41 ng/mL, p > .9999, and 1097 ± 90.75 ng/mL, p 
> .9999 respectively) group was also observed at 60 min for Glut and GABA (1120.75 ± 76.65 
ng/mL, p = .0043 and 1393.10 ± 52.34 ng/mL, p = .0081), respectively (Fig. 17C and 17F). 
Further, Ketamine significantly increased Glut levels at 120 (1071.42 ± 128.25 ng/mL, p = 
.0176) and 240 (1028.30 ± 46.72 ng/mL, p = .0064) min when compared to the control (716.1 
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± 92.41 ng/mL, p > .9999) whilst GABA had no significant change at those time points 
compared to the control (Fig. 17C and 17F). 
NE displayed a significant increase (1452.44 ± 134.64 ng/mL, p = .00160) at 5 min compared 
to the control (804 ± 60.21 ng/mL, p > .9999); this was followed by a sharp decline at 15 min 
(1035.10 ± 184.10 ng/mL, p = .1083) (Fig. 17B).  At 30 min, NE was significantly increased 
(1367.29 ± 221.80 ng/mL, p = .0321) when compared to the control group (804 ± 60.21 ng/mL, 
p > .9999). This significant increase in NE was also observed at 120 (1237.07 ± 134.26 ng/mL, 
p = .0176) and 240 (1189.44 ± 126.26 ng/mL, p = .0064) min post Ketamine administration 
(Fig. 17B). 
DA showed no significant increase at 5 min (29.79 ± 1.25 ng/mL, p = .1696), 15 min (29.91 ± 
1.71 ng/mL, p = .2432), and 30 min (28.79 ± 2.06 ng/mL, p = .8355) respectively (Fig. 17D).  
At 5- and 15-min post Ketamine administration, DA concentration remained constant, with a 
slight decrease at 30 min. This was followed by a significant increase in DA at 60 min (32.35 
± 2.32 ng/mL, p = .0081) compared to the control (28.53 ± 0.38 ng/mL, p > .9999).  DA levels 
decreased slightly at 120 min; however, it was still significantly (29.62 ± 0.50 ng/mL, p = 
.0394) increased when compared to the control group (28.53 ± 0.38 ng/mL, p > .9999). 
Between 120 min (29.62 ± 0.50 ng/mL, p = .0394) and 240 min (29.12 ± 0.52, p = .1829), the 
concentration levels remained constant (Fig. 17E). 
5-HT showed a significant increase (22.76 ± 0.56 ng/mL, p = .0362) at 5 min compared to the 
control group (21.55 ± 0.88 ng/mL, p > .9999) (Fig. 17E).  At 15 min (22.42 ± 1.00 ng/mL, p 
= .2311), 5-HT levels were lower than that at 5 min. This was followed by an increase in 5-HT 
levels at 30 min (23.25 ± 1.60 ng/mL, p = .1456) and 60 min (23.13 ± 0.81 ng/mL, p = .0367) 
compared to the control (21.55 ± 0,378703 ng/mL, p > .9999). From 60 min onwards, a slight 
decrease was observed; however, these levels remained constant from 120-240 min (Fig. 17E). 
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Figure 17: Brain concentrations (ng/mL) of; A) Ketamine; B) NE; C) Glut; D) DA; E) 5-HT and F) GABA at various time 
points following a single dose of Ketamine (15 mg/kg; IP). The data is presented as mean ± SD obtained from experiments 
performed in triplicate (N = 3). (****p < .0001; **p < .00100; *p < .05). 
 
Table 3: Summary of the pharmacokinetic parameters of Ketamine following a single dose 







Kel AUC0-inf  
(ng min/mL) 
351.33 ± 108.38 5 38.8968 0.0178 5464.343 
 
2.3.2. Effect of Ketamine on CREB and BDNF expression 
We further investigated the pharmacodynamic effects of Ketamine on BDNF and CREB gene 
expression at different time intervals during the treatment period. At 5 min post drug 
administration, BDNF was significantly downregulated (decrease in expression) by 0.96-fold 
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relative to the control (p < .0001). At 15 min, BDNF expression was upregulated (increase in 
expression) compared to that at 5 min (Fig. 18A).  
At 30 min, BDNF showed significant downregulation of 0.69-fold relative to the control (p = 
.0055).  BDNF expression was downregulated by 0.91-fold at 60 min compared to the control 
(p < .0001), while no significant difference was observed at 120 min (Fig. 18A). However, at 
240 min, BDNF was significantly downregulated by 0.71-fold relative to the control (p < .0017) 
(Fig. 18A). 
CREB showed no significant change compared to the control group at 5 and 15 min (Fig. 18B), 
with 30 min showing a non-significant increase of 0.14-fold relative to the control (p = .4866).  
At 60 min, CREB was significantly downregulated by 0.47-fold compared to the control (p < 
.0001) (Fig. 18B).  At 120 min, Ketamine decreased CREB expression by 0.13-fold compared 
to the control (p = .0418) (Fig. 18B).  Similarly, at 240 min post dosage, there was significant 
downregulation of CREB with a 0.25 relative fold change (Fig. 18B). 
 
Figure 18: Effect of Ketamine exposure on A) BDNF and B) CREB mRNA expression in brain tissue analyzed 
using qPCR. The data is presented as mean ± SD obtained from experiments performed in triplicate (N = 3). 
(****p < .0001; **p < .00100). 0 min was a control (Untreated). 
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2.4.  Discussion 
In this study, we investigated the pharmacodynamic effects of Ketamine in rat brain by 
assessing changes in the levels of neurotransmitters that are usually associated with depression.  
Ketamine levels increased rapidly to reach Cmax at 5 min followed by a gradual decrease at 15 
min to 240 min. This was consistent with a previous study conducted in our laboratory, which 
showed Ketamine s Cmax at 5 min post-administration(30) (Fig. 17A).  After 5- and 15-min 
post dosing of ketamine, glutamate and GABA showed a sharp, significant increase in 
concentration when compared to other neurotransmitters. The increase of glutamate levels was 
consistent with various reports in literature, which indicated that ketamine increases glutamate 
neurotransmission by both increased glutamate release and increased -amino-3-hydroxy-5-
methyl-4-isoxazole propionic acid receptor (AMPAR) expression (32-35). The observed 
phenomenon occurs via the ketamine disinhibition hypothesis, which proposes that Ketamine 
selectively blocks N-methyl-D-aspartate receptors (NMDARs) on GABAergic inhibitory 
interneurons, leading to the disinhibition of pyramidal neurons and enhanced glutamatergic 
release (32-35).  
GABA showed a similar trend to glutamate, where there was an increase in its concentration 
in the brain, this is consistent with a study conducted by  Ghosal et al. (2020), which showed 
an increase in GABA levels post ketamine administration (36). The upregulation of GABA is 
driven by a concurrent increase in glutamate levels and stimulation of the NMDARs, which 
also proceeds via the Ketamine disinhibition hypothesis.  However, it is important to note that 
the mechanism of GABA upregulation remains unclear. This may occur due to increased 
glutamate levels since glutamate serves as a precursor for GABA (19); or via an unknown 
ketamine mediated mechanism.   
The sharp increase in Glutamate and GABA levels at 5 and 15 min is in direct correlation with 
Ketamine concentration in the brain, where at 5- and 15-min Ketamine levels were at their 
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highest in brain samples (Fig. 17A, C and 17F). At 30 min post-administration, glutamate and 
GABA decreased in the brain when compared to 5 and 15 min respectively; this decrease is 
directly associated with the decreased concentration of Ketamine in the brain (Fig. 17A). 
The three monoamine neurotransmitters associated with depression (NE, DA, and 5-HT) were 
also investigated.  At 5 min post-administration, when ketamine concentrations were at their 
highest, DA showed no significant changes compared to NE and 5-HT, which showed a 
significant increase compared to the control group (Fig. 17A-17F).  Previous studies also 
reported increased levels of 5-HT and NE in brain regions such as the hippocampus and the 
cortical and midbrain upon administration of an acute dose of Ketamine (37-41).  The increase 
of 5-HT is assumed to occur when Ketamine enhances glutaminergic neurotransmission in the 
brain, via disinhibition hypothesis of Ketamine (blockade of NMDARs and stimulation of 
AMPARs), this is supported by a study conducted by  López-Gil, X. et al. (2019); which 
suggest that antidepressant-like effects of ketamine are caused by the stimulation of the 
prefrontal projection to the dorsal raphe nucleus and locus coeruleus caused by an elevated 
glutamate in the medial prefrontal cortex, which would stimulate release of serotonin  (37). 
This was further supported by a study conducted by Nishitani, N. et al (2014) (42) . Although 
ketamine increased NE regulation in the brain, there is no direct link between the two; Russell 
and Wiggins (2000) demonstrated that enhanced glutamate levels stimulate NE to be released 
in the rat brain (43). In addition, the upregulation of NE  cannot be linked to enhanced 5-HT 
regulation because projections of 5-HT neurons have an inhibitory effect on NE neurons (44). 
DA showed no significant increase at other time points except at 60 min post Ketamine 
administration, where a significant surge in levels of DA was observed (Fig. 17D). This 
observation was consistent with the study conducted by Kokkinou et al. (2018), which showed 
significantly increased levels of DA post administration of Ketamine (45). Similarly to 
glutamate, the upregulation of  DA is said to occur via the disinhibition hypothesis of Ketamine, 
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where NMDAR blockade on GABAergic interneurons leads to a projected regulation of 
midbrain dopamine neuronal cell bodies, which subsequently leads to an increase in pyramidal 
cell firing and increased excitation of dopamine neurons (45). 
The expression of BDNF and CREB gene was also investigated at similar time intervals as the 
neurotransmitters to determine the link between ketamine concentrations, neurotransmitter 
levels and expression of these genes. Several studies have shown that subanesthetic doses of 
Ketamine (10-30 mg/kg) induces BDNF expression in the brain by selectively blocking 
NMDAR expressed on GABAergic inhibitory interneurons which leads to a disinhibition of 
pyramidal neurons and enhanced glutamatergic release. The released glutamate then binds to 
and activates AMPAR resulting in enhanced BDNF expression and release, subsequently 
resulting in the activation of the tropomyosin receptor kinase B (TrkB) receptor and promotion 
of protein synthesis (46-50).  Our study showed a significant decrease in BDNF mRNA 
expression after 5 min post Ketamine (15 mg/kg) administration (Fig. 18A).  A recent study 
by Kim and Monteggia (2020), found that low dose of ketamine (5 mg/kg, IP) produces rapid 
antidepressant responses as well as critical molecular and synaptic effects that were not 
observed at higher doses (20 and 50 mg/kg, IP) (49).  A similar study conducted by Wu et al. 
(2020) also found that low-dose Ketamine (10 and 30 mg/kg) induced antidepressant effects, 
while high-dose Ketamine (100 mg/kg) induced cognitive impairment and pro-depression 
behavior (50). The study further indicated that 100 mg/kg Ketamine increased  BDNF mRNA 
expression after 24 hours (50).  Therefore, a possible explanation for the observed suppression 
of BDNF mRNA at 5 min post-administration of Ketamine (15 mg/kg), could be linked to 
higher concentration levels of Ketamine in the brain (Fig. 17A and Fig. 18A); as it is observed 
that ketamine mediated increase in BDNF expression have an inverse relationship with 
ketamine, since BDNF expression increases as Ketamine concentrations begin to decrease (Fig. 
17A and Fig. 18A). 
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At 5-30 min post administration of ketamine, there was no significant changes in the expression 
of CREB when compared to the control.  A study conducted by Réus et al. (2011), proved that 
CREB expression in the brain is not associated with the antidepressant response of Ketamine 
(51).  However, it has been shown that BDNF, via activating its tropomyosin receptor kinase 
B, can induce the activation of the mammalian target of rapamycin (mTOR) signaling and 
CREB signaling, which could explain the fluctuations observed in CREB expression (Fig. 18B) 
at 30-240 min post-administration of ketamine (52, 53).   
The implications of this study are significant with several experimental and clinical studies 
advocating the use of Ketamine in the treatment of MDD. There are various hypothesized 
mechanisms of ketamine in alleviating depression, such as disinhibition of glutamate release, 
blockade of extra-synaptic NMDARs, blockade of spontaneous NMDAR activation, the role 
of (2R,6R)-hydroxynorketamine (ketamine metabolite) and, inhibition of NMDAR- dependent 
bursting activity of lateral habeluna neurons (34, 54).  This study showed that the rapid anti-
depressive effect of ketamine is due to its influence on the glutamatergic pathway, which leads 
to alterations in various synaptogenic pathways in the brain, and enhances the release of 
glutamate, GABA, and the principal monoamine neurotransmitters (Fig. 19). 
In addition, it was observed that ketamine has inverse relationship with BDNF gene expression. 
The relationship between ketamine and CREB could not be established in this acute study; 
however, literature suggests that enhanced BDNF expression induces CREB signaling (52, 53).  
Therefore, this study found that out of many hypothesized Ketamine s mechanisms of action, 
the disinhibition of glutamate hypothesis was the primary mechanism of action that 
subsequently enhances synaptogenesis in the central nervous system, allowing the other 
hypothesized mechanisms to be initiated.  Hence, ketamine s disinhibition of glutamate 
hypothesis was found to be the central mechanism in the rapid amelioration of MDD.  
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Figure 19: Schematic diagram summarizing the pharmacodynamic effects of Ketamine (15 mg/kg.b.w) as found 
in this study. Created by the Author. 
 
2.5.  Conclusion 
This study demonstrated that ketamine alleviates depression by significantly altering the 
glutamatergic system which occurs via the disinhibition of glutamate release, this enhances 
central nervous synaptogenesis, correcting the imbalance of neurotransmitters and proteins 
associated with the pathophysiology of depression. This study shows that the anti-depressive 
action of ketamine may be two-fold in that its initial alleviation of depressive symptoms is due 
to its effect on the glutamatergic system, which is latter followed by an increase in BDNF 
expression, a target of traditional antidepressants. However, the findings of this study are not 
completely inclusive, hence, more studies are still needed. 
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3.1.  Summary and Conclusion 
Ketamine is currently aproved by the US FDA as anesthetic drug, that is being used off-label 
for pain manangement (acute and chronic), and most recently as an antidepressant in the 
treatment of MDD (1-3). Several clinical studies have indicated that subanesthetic doses of 
ketamine infusions provide rapid relief of depressive symptoms in people suffering from MDD 
and TRD (4-6). This study investigated the pharmacodynamic effects of ketamine on several 
vital brain neurotransmitters in the treatment of MDD. These included the monoamine 
neurotransmitters (DA, 5-HT, and NE) and amino acid neurotransmitters (Glut and GABA), 
which have been shown to be deficient or altered in MDD patients and in depressed animal 
models (7-12). The study further investigated the effects of ketamine on transcription factors, 
BDNF and CREB expression in the brain as they have been linked to the pathophysiology of 
MDD and that are targets of conventional antidepressant drug classes (13-15).   
Twenty-one healthy male SD rats in a mass range of 120-130 g were administered 15 mg/kg 
of ketamine intraperitonially at different time intervals. LC-MS/MS was used to quantify or 
assess concentration levels of neurotransmitters, whilst gene expression was achieved using 
qPCR.  The pharmacokinetic results showed that ketamine reached a maximum concentration 
of 351.33 ± 108.38 ng/mL at 5 min post drug administration (Fig. 17A). This finding was 
similar to a  previous study conducted in our laboratory which showed that ketamine 
concentrations in the brain increased rapidly to its Cmax in 5 min thereafter decreased gradually 
to its trough concentrations (16). 
The results obtained showed that at Cmax of ketamine, Glut and GABA had a significant 
increase in their concentration compared to the monoamine neurotransmitters. Throughout the 
study, Glut and GABA had a higher concentration in the brain compared to the monoamine 
neurotransmitters (Fig. 17A-17F). These findings indicated that ketamine mainly affects the 
glutamatergic and GABAergic neurotransmission systems compared to the monoaminergic 
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neurotransmission system.  This is due to ketamine s disinhibition of glutamate hypothesis, 
which indicates that ketamine selectively blocks NMDRs on GABAergic inhibitory 
interneurons, which results to a disinhibition of pyramidal neurons and improved glutamatergic 
release, which further enhances GABAergic neurotransmission (Fig. 19). The observed 
increase in monoamine neurotransmitters could be linked to the same hypothesized 
disinhibition mechanism of ketamine. During NMDAR blockage and AMPAR stimulation, 
there is an increase in new synaptic connections and improved brain plasticity, which 
subsequently results in increased monoamine neurotransmitters and alleviation of depressive 
symptoms (17). 
The study also found that at high ketamine concentration levels, the gene expression of BDNF 
was significantly downregulated while CREB  gene had no significant change compared to 
the control groups. However; as concentration levels of ketamine declined, there was an 
upregulation in the expression of the BDNF gene , indicating that there is a delay in ketamine s 
effect in the expression of BDNF, and that upregulation of BDNF is responsible for the 
signaling of CREB (Fig. 18A and B); this is supported by literature which indicates that 
enhanced BDNF expression induces CREB signaling (18, 19) 
This study showed that the rapid anti-depressive effect of ketamine is due to its influence on 
the glutamatergic pathway, which leads to alterations in various synaptogenic pathways in the 
brain, by enhancing the release of glutamate, GABA and altering the principal monoamine 
neurotransmitters (Fig. 19). 
In conclusion, the study demonstrated that ketamine s disinhibition of glutamate hypothesis is 
the vital key mechanism of action in the treatment of MDD since it enhances central nervous 
synaptogenesis and corrects the imbalance of neurotransmitters, and genes associated with the 
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pathophysiology of depression.  In addition, this study indicated that there is a delay in BDNF  
response to ketamine administration (Inverse relationship).  
This research had some limitations in that we did not investigate the long-term effects of 
ketamine administration, it is therefore recommended that a similar study is carried out over a 
long period of time. This study should also include the use of depressed animal models. 
Depression can will be induced in rats by subjecting them to several manipulations of chronic 
unpredictable stress (CUS) over a period of a month.  This will allow for animal behavioral 
tests to be conducted and compare behavioral outcomes in response to ketamine therapy in 
both depressed animal models and healthy animals. Furthermore, it will further allow us to 
determine if chronic administration of ketamine impacts the expression of transcription factor 
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Figure 22: A) LC-MS/MS chromatogram of 5-HT     RT 1.17 ; B) 5-HT precursor spectrum showing [M+H]+ at 177.00 m/z . 
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Figure 23: A) LC-MS/MS chromatograph o  GABA     RT 0.64 ; B) GABA    [M+H]+  104.35 /  . 




Figure 24: A) LC-MS/MS   DA     RT 0.78 ; B) DA precursor spectrum showing [M+H]+ at 154.08 m/z . 
 
 
















Figure 26: A) LC-MS/MS   GLUT     RT 0.65 min; B) GLUT precursor spectrum showing [M+H]+ at 148.05 m/z . 
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Figure 27: LC-MS/MS chromatogram showing  DA, GABA, GLU, NE, 5-HT, IS and ketamine in brain sample at 5 min post-administration of 15 mg/kg ketamine. 
